Clinical trials: Prostate Cancer Stage
Prostate Cancer
HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer
The purpose of this study is to evaluate High-dose rate (HDR) brachytherapy (1 vs 2 fractions on single implant) as monotherapy for the treatment of low risk and intermediate risk prostate cancer
- Trial name
- BRP2 (NCT03424694)
- Testing
- HDR brachytherapy as monotherapy
- Where
- Canada
- Volunteers
- 199 people
- Sponsor
- CR-CSSS Champlain-Charles-Le Moyne
Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- HYDRA (NCT04945642)
- Testing
- High-Dose Rate Brachytherapy, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostatic Neoplasm
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
The purpose of this study is to evaluate a short course (five radiation treatments) of very focused ("stereotactic") external beam radiation therapy for the treatment of early stage prostate cancer.
- Trial name
- NCT01540994
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sharp HealthCare
Prostate Cancer
Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
The purpose of this study is to examine the safety and effectiveness (how well the drug works) of two different doses (3 mg/kg and 10 mg/kg) of Ipilimumab (Yervoy™) in patients with metastatic castration resistant prostate cancer.
- Trial name
- NCT02279862
- Testing
- Ipilimumab
- Where
- 43 sites in United States, Australia and 7 more
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
Localized Prostate Cancer
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Background: Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help.
- Trial name
- NCT05155046
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Bone Metastases, Breast Cancer
Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation
Zoledronic acid (Zometa) belongs to a class of drugs called bisphosphonates. Bisphosphonates are used in bone metastases to keep the cancerous lesion under control in the bone and to help prevent calcium level elevations in the…
- Conditions
- Bone Metastases, Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00264420
- Testing
- zoledronic acid
- Volunteers
- 4 people
- Sponsor
- The Cleveland Clinic
Prostate Cancer
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
This study will compare the safety and efficacy of curative radiotherapy to the prostate and lymph glands given in 5 visits to that of prostate alone radiotherapy given in 5 visits, in men with high risk localised prostate cancer.
- Trial name
- PACE-NODES (NCT05613023)
- Testing
- SBRT
- Where
- 42 sites in Ireland, New Zealand and 1 more
- Volunteers
- 1,128 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Metastatic Castration-Resistant Prostate Cancer
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
- Trial name
- NCT06629779
- Testing
- PF-06821497, Enzalutamide
- Where
- 231 sites in United States, Argentina and 25 more
- Volunteers
- 900 people
- Sponsor
- Pfizer
Hormone Refractory Prostate Cancer, Recurrent Prostate Cancer
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
This randomized phase II trial is studying the side effects and how well giving cediranib maleate together with or without dasatinib works in treating patients with hormone-resistant prostate cancer resistant to treatment with…
- Trial name
- NCT01260688
- Testing
- cediranib maleate, dasatinib
- Where
- 8 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma Prostate
Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib
Multiparametric assesment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study
- Trial name
- MERIDIAN (NCT05265988)
- Testing
- Cabozantinib
- Where
- Italy
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Alfredo Berruti
Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma
Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
This phase II trial tests how well M1774 works in treating patients with prostate cancer that does not respond to treatment (refractory) and that has a mutation in the gene responsible for making the speckle type BTB/POZ protein…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05828082
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen deprivation therapy(ADT) in men with biochemical…
- Trial name
- NCT00658697
- Testing
- Docetaxel, Bevacizumab, ADT
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
MRI in Diagnosing Prostate Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help find prostate cancer and learn the extent of disease.
- Trial name
- NCT01292291
- Testing
- biologic sample preservation procedure, laboratory biomarker analysis, study of socioeconomic and demographic variables
- Volunteers
- 714 people
- Sponsor
- University College London Hospitals
Prostate Cancer Patients Undergoing Radical Prostatectomy
PSMA-Targeted Intraoperative Fluorescent Imaging Agents (DGPR1008): Validation Across Different Time Windows
a Phase II, single-arm, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and the effectiveness of near-infrared fluorescence imaging during surgery.
- Trial name
- DGPR1008-04 (NCT07387510)
- Testing
- 12 h before RP, 24 h before RP, 36 h before RP
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Haitao Niu, MD
Prostate Cancer
A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer
In this study, up to 21 patients with metastatic prostate cancer will receive UV1 (a therapeutic synthetic peptide vaccine) at different dose levels.
- Trial name
- UV1/hTERT2012P (NCT01784913)
- Testing
- UV1 synthetic peptide vaccine and GM-CSF
- Where
- Norway
- Volunteers
- 22 people
- Sponsor
- Ultimovacs ASA
Prostatic Neoplasms
A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer
This study is being offered to patients who have hormone resistant prostate cancer (HRPC). This means that their prostate cancer is no longer responding to standard hormonal therapy.
- Trial name
- OTT10-06 (NCT01545882)
- Testing
- Degarelix
- Where
- 3 sites in Canada
- Volunteers
- 5 people
- Sponsor
- Ottawa Hospital Research Institute
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
This clinical trial was done to show whether a radioactive drug (I-131-1095) that binds to prostate-specific membrane antigen (PSMA) is useful in treating metastatic prostate cancer that is positive for PSMA.
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate
- Trial name
- ARROW (NCT03939689)
- Testing
- I-131-1095, Enzalutamide
- Where
- 27 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostatic Neoplasms
The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation
This study utilizes a conventional phase I study design with a '3+3 cohort expansion' design(15), to determine the maximum tolerated dose(MTD) of 1) Cabazitaxel, in Part A, and 2) Radiotherapy, in Part B.
- Trial name
- NCT01981668
- Testing
- cabazitaxel
- Sponsor
- Nova Scotia Cancer Centre
MCRPC
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating the efficacy and safety of HC-1119 soft capsules versus placebo in mCRPC patients who have failed or become intolerant to the…
- Trial name
- NCT03851640
- Testing
- HC-1119
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Prostate Cancer
Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer
RATIONALE: Celecoxib may be an effective treatment for early stage prostate cancer. It is not yet known if celecoxib is more effective than no treatment before surgery for prostate cancer.
- Trial name
- NCT00022399
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.